Filing Details
- Accession Number:
- 0000929638-22-001901
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-20 17:42:47
- Reporting Period:
- 2022-12-20
- Accepted Time:
- 2022-12-20 17:42:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1761918 | Erasca Inc. | ERAS | () | DE |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1583977 | Cormorant Asset Management, Lp | 200 Clarendon Street 52Nd Floor Boston MA 02116 | No | No | No | No | |
1599214 | Bihua Chen | C/O Cormorant Asset Management, Llc 200 Clarendon Street, 52Nd Floor Boston MA 02116 | No | No | No | No | |
1618442 | Cormorant Global Healthcare Master Fund, Lp | 200 Clarendon Street, 52Nd Floor Boston MA 02116 | No | No | No | No | |
1747677 | Cormorant Private Healthcare Fund Ii, Lp | 200 Clarendon Street, 52Nd Floor Boston MA 02116 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-12-13 | 307,692 | $6.50 | 10,813,246 | No | 4 | P | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnotes |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | $5.81 | 2031-04-11 | 166,666 | 166,666 | Direct | |
Common Stock | Stock Option (right to buy) | $5.35 | 2023-06-22 | 2032-06-21 | 40,000 | 40,000 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2031-04-11 | 166,666 | 166,666 | Direct |
2032-06-21 | 40,000 | 40,000 | Direct |
Footnotes
- Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
- Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.
- Shares reported herein as purchased on December 9, 2022 were purchased by the Master Fund.
- Stock option grant for 166,666 shares, 41,667 shares of which become exercisable on 3/16/2022 and 124,999 shares of which become exercisable thereafter in equal monthly installments through 3/16/2025.
- Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.